From injection therapies to natalizumab: views on the treatment of multiple sclerosis [0.03%]
从注射疗法到那他珠单抗：关于多发性硬化症治疗的观点
Roberto Bomprezzi,Darin T Okuda,Yazan J Alderazi et al.
Roberto Bomprezzi et al.
Discoveries of the mechanisms that underlie the pathogenesis of multiple sclerosis have been acquired at an impressive rate over the last few decades and, as a consequence, a growing number of treatments are becoming available for this dise...
Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis? [0.03%]
运动与多发性硬化病程的关系：运动能否延缓多发性硬化的进展？
Ulrik Dalgas,Egon Stenager
Ulrik Dalgas
It has been suggested that exercise (or physical activity) might have the potential to have an impact on multiple sclerosis (MS) pathology and thereby slow down the disease process in MS patients. The objective of this literature review was...
Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany [0.03%]
德国依姆替康酮治疗多发性硬化患者继发急性白血病的发病率
Anke Stroet,Claudia Hemmelmann,Michaela Starck et al.
Anke Stroet et al.
Background: The incidence of therapy-related acute leukaemia (TRAL) in mitoxantrone treatment in multiple sclerosis (MS) is controversially discussed. Met...
Giorgio Lambru,Manjit S Matharu
Giorgio Lambru
Chronic daily headache is a major worldwide health problem that affects 3-5% of the population and results in substantial disability. Advances in the management of headache disorders have meant that a substantial proportion of patients can ...
Challenges and controversies in the medical management of primary and antithrombotic-related intracerebral hemorrhage [0.03%]
原发性和抗血栓形成相关性脑内出血的医疗管理面临的挑战和争议
Michael Moussouttas
Michael Moussouttas
Intracerebral hemorrhage (ICH) represents 10-15% of all cerebrovascular events, and is associated with substantial morbidity and mortality. In contrast to ischemic cerebrovascular disease in which acute therapies have proven beneficial, ICH...
Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy? [0.03%]
帕金森病的非运动性预后：脑深部刺激优于多巴胺替代治疗吗？
Rupam Borgohain,Rukmini Mridula Kandadai,Afshan Jabeen et al.
Rupam Borgohain et al.
Nonmotor symptoms are an integral part of Parkinson's disease and cause significant morbidity. Pharmacological therapy helps alleviate the disease but produces nonmotor manifestations. While deep brain stimulation (DBS) has emerged as the t...
Smoking: effects on multiple sclerosis susceptibility and disease progression [0.03%]
吸烟和多发性硬化症易感性和疾病进展的关系
Dean M Wingerchuk
Dean M Wingerchuk
Multiple sclerosis (MS) is associated with both genetic and environmental factors that influence disease susceptibility. Exposure to cigarette smoke is emerging as a viable environmental risk factor for MS that contributes to both increased...
Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis [0.03%]
米托蒽醌治疗后的治疗减毒：一项评价干扰素β-1a皮下注射在复发缓解型多发性硬化症患者中疗效的IV期、多中心、开放标签、随机研究结果
Peter Rieckmann,Fedor Heidenreich,Michael Sailer et al.
Peter Rieckmann et al.
Objective: The objective of this study was to assess the effect of treatment with interferon (IFN) β-1a, 44 µg subcutaneously (sc) three times weekly (tiw), on clinical and magnetic resonance imaging (MRI) outcomes in p...
Clare M Eddy,Hugh E Rickards,Andrea E Cavanna
Clare M Eddy
Effective treatment of epilepsy depends on medication compliance across a lifetime, and studies indicate that drug tolerability is a significant limiting factor in medication maintenance. Available antiepileptic drugs (AEDs) have the potent...
Gila Bronner,David B Vodušek
Gila Bronner
Nonmotor symptoms, among them sexual dysfunction, are common and underrecognized in patients with Parkinson disease; they play a major role in the deterioration of quality of life of patients and their partners. Loss of desire and dissatisf...